This site is intended for Healthcare Professionals only.

GPhC, CMA talk tough on COVID-19 profiteering

Date:

Share post:

The Competition and Markets Authority (CMA) has launched a taskforce to tackle unscrupulous business practices during the COVID-19 crisis.

The competition watchdog had earlier this month asked retailers to not exploit the current situation to take advantage of people, warning against practices like charging excessive prices or making misleading claims about their products.

Industry regulator General Pharmaceutical Council (GPhC) has also reacted strongly against such practices.

“The actions of a small minority are raising concerns and anger within the profession itself and more widely,” commented Duncan Rudkin, GPhC chief executive.

“Profiteering to take selfish advantage of the current challenging situation, whether with prices of shortage products or locum rates, risks bringing the profession into disrepute at a time when public confidence generally is so fragile, and so important.”

The CMA said it has already contacted traders and platforms regarding excessive pricing of hand sanitiser.

“The intervention in the economy necessitated by public health policy may have a substantial impact on competition, with the risk of an increase in consumer detriment. That’s why this taskforce is needed,” said Andrew Tyrie, the CMA chairman.

The taskforce will identify harmful sales and pricing practices as they emerge and warn firms suspected of exploiting these exceptional circumstances through unjustifiable prices or misleading claims.

Read More: Birmingham pharmacy charges £19.99 for bottle of Calpol, sparks outrage on Twitter over alleged ‘profiteering’

It will also take enforcement action if there is evidence that firms may have breached competition or consumer protection law and fail to respond to warnings.

“We have a range of options at our disposal, from warnings to enforcement action to seeking emergency powers. We hope that such action will not be necessary, but we will do whatever is required to stop a small minority of businesses that may seek to exploit the present situation,” said Andrea Coscelli, the CMA chief executive.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Haleon to close Maidenhead manufacturing site affecting 435 jobs

Despite the closure, Haleon will retain its presence in the UK with corporate offices in Weybridge and London Haleon,...

UK pharmacies cut prices for weight-loss drugs Wegovy, Mounjaro amidst escalating competition

Obesity experts raise concern that retail marketing of weight-loss drugs could trivialise their side-effects   British pharmacies and slimming...

MHRA says many online pharmacies are ‘unregulated’,’ illegal’, or ‘fraudulent’

MHRA's latest initiative aims to empower consumers in the fight against online pharmacy frauds The Medicines and Healthcare products...

MHRA outlines strategic approach to AI regulation in healthcare for patient safety

MHRA's strategic principles aim to foster innovation while upholding rigorous standards of patient safety and regulatory integrity In a...